Success Metrics

Active Trials
3(33%)

Phase Distribution

Ph not_applicable
1
11%
Ph phase_2
5
56%
Ph phase_3
1
11%
Ph phase_1
1
11%

Phase Distribution

1

Early Stage

5

Mid Stage

1

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
1(12.5%)
Phase 2Efficacy & side effects
5(62.5%)
Phase 3Large-scale testing
1(12.5%)
N/ANon-phased studies
1(12.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

9

all time

Status Distribution
Active(8)
Other(1)

Detailed Status

Not yet recruiting5
Recruiting3
unknown1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
3
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 11 (12.5%)
Phase 25 (62.5%)
Phase 31 (12.5%)
N/A1 (12.5%)

Trials by Status

unknown111%
not_yet_recruiting556%
recruiting333%

Recent Activity

3 active trials
Showing 5 of 9
not_yet_recruiting

Microbiota in Neoadjuvant Chemoimmunotherapy for NSCLC

NCT07752589
not_yet_recruitingphase_2

Neoadjuvant Docetaxel, Cisplatin, and Dual Immunotherapy for Sinonasal Carcinoma

NCT07645846
not_yet_recruitingphase_3

A Clinical Study of QL1706 Combined With Chemotherapy as Neoadjuvant Therapy for High-Risk Locally Advanced Cervical Cancer

NCT07613567
recruitingphase_2

Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CRIS-2 Trial）

NCT06509568
not_yet_recruitingphase_2

Neoadjuvant Immunochemotherapy and Postoperative Adjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma Invading the Skull Base

NCT07145931
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT07752589

Microbiota in Neoadjuvant Chemoimmunotherapy for NSCLC

Not Yet Recruiting
NCT07645846Phase 2

Neoadjuvant Docetaxel, Cisplatin, and Dual Immunotherapy for Sinonasal Carcinoma

Not Yet Recruiting
NCT07613567Phase 3

A Clinical Study of QL1706 Combined With Chemotherapy as Neoadjuvant Therapy for High-Risk Locally Advanced Cervical Cancer

Not Yet Recruiting
NCT06509568Phase 2

Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CRIS-2 Trial）

Recruiting
NCT07145931Phase 2

Neoadjuvant Immunochemotherapy and Postoperative Adjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma Invading the Skull Base

Not Yet Recruiting
NCT07121374Phase 1

NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study

Recruiting
NCT07092449Not Applicable

Pucotenlimab Combined With Chemotherapy as Perioperative Treatment for Locally Advanced Gastroesophageal Junction Carcinoma

Not Yet Recruiting
NCT05468242Phase 2

Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy

Recruiting
NCT02976142Phase 2

The Efficacy of Surgical Treatment After Neoadjuvant Chemotherapy Plus Intraperitoneal Immunotherapy Versus Chemotherapy Alone for Patients With Positive Wash Cytology Gastric Cancer

Unknown

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9